Search Results
Mar 17, 2026, 09:30 ET Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases
clinical‑stage biotech advancing RNA medicines by accelerating a virtuous cycle of platform and pipeline innovation—improving lives worldwide. Backed by a substantial and growing intellectual property portfolio, the company has built a proprietary, differentiated RNA delivery and engineering platform
More news about: Innorna Co., Ltd.
Mar 17, 2026, 09:30 ET Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases
clinical‑stage biotech advancing RNA medicines by accelerating a virtuous cycle of platform and pipeline innovation—improving lives worldwide. Backed by a substantial and growing intellectual property portfolio, the company has built a proprietary, differentiated RNA delivery and engineering platform
More news about: Innorna Co., Ltd.
Mar 17, 2026, 09:00 ET Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Mar 17, 2026, 06:38 ET MGI Tech and Predica Diagnostics Accelerate Cervical Cancer Screening on DNBSEQ Platforms
global expansion to follow.About Predica DiagnosticsPredica Diagnostics B.V. is a precision-oncology company developing targeted RNA sequencing tests for early cancer detection, risk stratification, and treatment guidance. Founded as a spin-off from Radboudumc, Predica aims to bring
More news about: MGI Tech Co., Ltd.
Mar 16, 2026, 23:00 ET Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 16, 2026, 23:00 ET Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 16, 2026, 23:00 ET Ribo presentará datos sobre la administración ex-hepática en la Conferencia RNA Leaders Europe
-- Suzhou Ribo Life Science Co., Ltd. ("Ribo" o "la Compañía", código Hong Kong Stock Exchange: 6938) ha sido invitada a dar una ponencia en la Conferencia RNA Leaders Europe que se celebrará en Viena (Austria) el 19 de marzo, una de las conferencias más importantes sobre oligonucleótidos.
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 16, 2026, 23:00 ET 瑞博生物將在歐洲RNA Leaders會議報告siRNA肝外靶向最新研究進展
View original content to download multimedia:https://www.prnewswire.com/apac/zh/news-releases/rna-leaderssirna-302715370.htmlSOURCE 蘇州瑞博生物技術股份有限公司
More news about: 蘇州瑞博生物技術股份有限公司
Mar 16, 2026, 21:00 ET Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
extensive wet lab capabilities to accelerate the discovery of small molecules, antibodies, peptides, fusion proteins, PROTACs, molecular glues, and RNA-targeting compounds. Looking ahead, Viva Biotech will further strengthen its AI algorithm development and leverage its AI platform in drug discovery
More news about: Viva Biotech
Mar 16, 2026, 21:00 ET Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
extensive wet lab capabilities to accelerate the discovery of small molecules, antibodies, peptides, fusion proteins, PROTACs, molecular glues, and RNA-targeting compounds. Looking ahead, Viva Biotech will further strengthen its AI algorithm development and leverage its AI platform in drug discovery
More news about: Viva Biotech
Mar 16, 2026, 09:00 ET Co-Diagnostics to Present at Medical Korea 2026
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Mar 16, 2026, 08:00 ET Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE
March 16, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its novel
More news about: Argo Biopharmaceutical Co., Ltd
Mar 12, 2026, 09:00 ET Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Mar 12, 2026, 08:27 ET Bota uvádí na trh SAION AI, fyzickou platformu pro biovýrobu na bázi AI
Porozumění literatuře: 70,7 % u LitQA+SuppQA – překonání předních modelů pro všeobecné použitíSekvenční uvažování: 88,2 % v úlohách SeqQA pro DNA, RNA a proteiny.Genetické inženýrství: 84,9 % v benchmarcích pro úpravu genů a klonování.Vědecký objev: 89,6 % v benchmarku BAIS-SD.Validace
More news about: Bota
Mar 12, 2026, 07:45 ET Singular Genomics Names the Spatial Technologies Unit at Beth Israel Deaconess Medical Center a G4X™ Center of Excellence
G4X™, commercially launched in February 2026, enables integrated in situ readout of 1,000-plex RNA, 18-plex protein, and fH&E morphology simultaneously on up to 128 FFPE samples per run, delivering subcellular resolution
More news about: Singular Genomics
Mar 12, 2026, 07:00 ET PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer
across four academic and clinical centers in the United States and Sweden, with a median follow-up of 10 years. AidaBreast integrates targeted NextGen RNA expression with multiplex protein biomarker expression and spatial biology to provide insight into both recurrence risk and differential benefit from
More news about: Prelude Corporation
Mar 11, 2026, 19:56 ET Bota Luncurkan SAION AI -- Platform "Physical AI" untuk Biomanufaktur
SuppQA, melampaui sejumlah model AI general-purpose terkemuka.Penalaran sekuens biologis: 88,2% untuk SeqQA saat mengerjakan tugas DNA, RNA, dan protein.Rekayasa genetika: 84,9% untuk tolok ukur pengeditan gen dan kloning.Penemuan ilmiah: 89,6% untuk tolok ukur BAIS-SD.Validasi
More news about: Bota
Mar 11, 2026, 14:54 ET Bota bringt SAION AI auf den Markt - Physical AI-Plattform für die Bioproduktion
Literaturverständnis: 70,7 % bei LitQA+SuppQA – übertrifft die führenden AllzweckmodelleSequenzbasiertes Reasoning: 88,2 % bei SeqQA für DNA-, RNA- und ProteinaufgabenGentechnologie: 84,9 % bei den Benchmarks für Genbearbeitung und KlonenWissenschaftliche Entdeckung: 89,6 % beim
More news about: Bota
Mar 11, 2026, 13:33 ET Bota lança SAION AI, a plataforma física de IA para biomanufatura
literatura: 70,7% em LitQA +SuppQA, superando os principais modelos de uso geralRaciocínio em sequência: 88,2% em SeqQA em tarefas de DNA, RNA e proteína.Engenharia genética: 84,9% em benchmarks de edição e clonagem de genes.Descoberta científica: 89,6% no benchmark BAIS-SD.A
More news about: Bota
Mar 11, 2026, 13:03 ET Bota spúšťa SAION AI -- platformu fyzickej AI pre biovýrobu
zdrojom: 70,7 % na LitQA+SuppQA – prekonáva popredné modely na všeobecné použitieZdôvodnenie postupnosti: 88,2 % na SeqQA v rámci zadaní DNA, RNA a proteínov.Genetické inžinierstvo: 84,9 % v benchmarkoch pre génovú úpravu a klonovanie.Vedecké objavy: 89,6 % na benchmarku BAIS-SD.Validácia
More news about: Bota
Mar 11, 2026, 11:52 ET Skyhawk Therapeutics ernennt Aaron Deves zum Chief Commercial Officer für die Vermarktung von SKY-0515 zur Behandlung der Huntington-Krankheit
Therapeutics, Inc., ein Biotechnologieunternehmen in der klinischen Entwicklungsphase, das neuartige niedermolekulare Therapien entwickelt, um kritische RNA-Ziele für eine Reihe von schwer zu behandelnden neurologischen Krankheiten zu modulieren, gibt die Ernennung von Aaron Deves zum Chief Commercial Officer
More news about: Skyhawk Therapeutics
Mar 11, 2026, 10:41 ET Bota uruchamia SAION AI - platformę fizycznej sztucznej inteligencji dedykowaną bioprodukcji
70,7% w LitQA+SuppQA - przewyższając wiodące modele ogólnego przeznaczenia,Rozumowanie sekwencyjne: 88,2% w SeqQA w zadaniach dotyczących DNA, RNA i białek,Inżynieria genetyczna: 84,9% w testach porównawczych dotyczących edycji genów i klonowania.Odkrycia naukowe: 89,6% w teście
More news about: Bota
Mar 11, 2026, 09:03 ET Bota ra mắt SAION AI -- Nền tảng AI Vật lý cho sản xuất sinh học
đánh giá LitQA+SuppQA — vượt qua các mô hình đa năng hàng đầuSuy luận trình tự: đạt 88,2% trên SeqQA đối với các nhiệm vụ liên quan đến DNA, RNA và protein.Kỹ thuật di truyền: đạt 84,9% trên các bộ đánh giá chuẩn về chỉnh sửa gen và nhân bản.Khám phá khoa học: đạt 89,6% trên
More news about: Bota
Mar 11, 2026, 07:37 ET Botaはバイオ製造向けフィジカルAI（Physical AI）プラットフォーム「SAION AI」を発表
AIは、複数のライフサイエンスAIベンチマークにおいて SOTA のパフォーマンスを実証し、AIサイエンティストシステムとしての能力を検証しました。主な成果文献の理解：LitQA+SuppQAで70.7％を達成 - 主要汎用モデルを上回しますシーケンス推論：DNA、RNA、タンパク質タスクにわたるSeqQAで88.2%を達成します。遺伝子工学：遺伝子編集とクローニングのベンチマークで84.9%を達成します。科学的発見：BAIS-SDベンチマークで89.6%を達成します。現実世界での検証により、SAION AIが文献調査からウェットラボでの組み立てに至るまでの完全な研究を、90％以上の精度で自律的に完了できることが確認されています。自律的なバイオ製造に向けてSAION
More news about: Bota
Mar 11, 2026, 04:00 ET ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)
biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ATX-01 for the treatment of Myotonic Dystrophy type 1 (DM1). ATX-01 is ARTHEx's investigational RNA therapeutic designed to
More news about: ARTHEx Biotech